ArticleBMC microbiology2026
Weissella cibaria-derived dextran alleviates cisplatin-induced kidney injury by remodeling the gut microbiota.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCisplatin, a first-line chemotherapeutic agent, is severely limited by its dose-limiting nephrotoxicity. The gut-kidney axis has emerged as a critical pathway, where cisplatin-induced intestinal injury aggravates renal damage. While exopolysaccharides (EPS) from probiotics are known for health benefits, their role against cisplatin toxicity is unclear. This study aimed to investigate the protective effects and mechanisms of EPS-2, a dextran from Weissella cibaria MW030, against cisplatin-induced acute kidney injury.
resultsPretreatment with EPS‑2 significantly alleviated renal histopathological damage, apoptosis, oxidative stress, and inflammation, while also restoring intestinal barrier integrity by enhancing mucin and tight junction protein expression. Gut microbiota analysis indicated that EPS‑2 enriched short-chain fatty acids (SCFAs)‑producing bacteria such as unclassified_f_Muribaculaceae and suppressed LPS‑producing potential pathogens including Escherichia‑Shigella. These compositional changes were accompanied by elevated fecal SCFA levels and reduced circulating LPS, which may collectively contribute to the mitigation of renal injury. Notably, these protective effects were abolished in pseudo‑germ‑free mice, underscoring the critical role of the gut microbiota in the action of EPS‑2.
conclusionsEPS-2 has the potential to be a promising postbiotic for preventing cisplatin-induced AKI, intestinal barrier dysfunction, and gut microbiota dysbiosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.